Antituberculosis drugs are associated with a significant number of AR that can cause significant morbidity, prolonged hospital stay and even death. Our results show that alcoholism and levels of CD4 < 350 cells/mm(3) were significantly associated with a high risk of AR and hepatitis B and C and levels of CD4 < 350 cells/mm3 were also significantly associated with hepatotoxicity.
ObjectivesDespite non‐small cell lung cancer (NSCLC) high prevalence and increasing incidence, evidence specific to the elderly and very elderly is sparse. To retrospectively compare characterization and approach of NSCLC patients (pts) aged 70‐79 and ≥80 years.MethodsWe performed a retrospective analysis of 297 adult NSCLC pts who registered and initiated NSCLC management in our Pulmonology Oncology Unit from January 2013 to December 2016 corresponding to 38.2% of all NSCLC patients (n = 778). Demographic data and lung cancer management were analysed.ResultsPts were categorized as elderly (n = 211, 71.0%) and very elderly (n = 86, 29.0%). Very elderly pts had worse Eastern Cooperative Oncology Group performance status (P = 0.047), higher Charlson age comorbidity index (P < 0.001) and the majority had stage IV cancer (66.3%, P = 0.04). The first management option in very elderly pts was chemotherapy (CTX) (30.2%, P = 0.37) and in elderly pts was multimodal therapy (30.3%, P ≤ 0.001). Support therapy and first‐line targeted (EGFR or ALK‐positive) were more common in the very elderly (23.6%, P = 0.01; 17.4% P = 0.002, respectively). Curative radiation or surgery rates did not differ between groups. Reasons for premature first‐line CTX stop, toxicity and hospitalization did not differ. Death rate (69.7% vs 63.5% for very elderly and elderly, respectively) and mean survival since diagnosis (11.5 vs 11.6 months for very elderly and elderly, respectively) did not differ.ConclusionsThere were significant differences in pts characteristics having the very elderly more multimorbidity and advanced state of disease. First management options were significantly different with respect to multimodal, targeted and support therapy.
Background: Genetic aberrations in KRAS and TP53 were common in NSCLC, and were indicated to be associated with efficacious immunotherapy. However, the inter-relation between these two gene mutations were largely unknown. We hereby interrogate the inter-relation by meta-cohort analysis involving 8 cohorts of 1129 NSCLC patients receiving ICIs.Methods: We retrospectively collected the clinical and mutational data of the patients with EGFR/ALK WT non-squamous NSCLC receiving ICI treatment (the 3DMed cohort, n¼37). In addition, another 7 public cohorts (SNCC, Van Allen, Rizvi-34, Rizvi-240, MSKCC-75, MSKCC-350, and POPLAR/OAK) involving data from 1092 patients were included to comprehensively explore the impact of KRAS/TP53 mutations on ICI benefit.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.